#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute graft versus host disease in intestine Anaplastic thyroid cancer Non-Hodgkin's lymphoma Thrombotic thrombocytopenic purpura Dent's disease Thrombocytopenia Progressive familial intrahepatic cholestasis Osteosarcoma metastatic Giant cell tumour of tendon sheath Breast angiosarcoma Chronic granulomatous disease Ependymoma Palmar-plantar erythrodysaesthesia syndrome Philadelphia positive acute lymphocytic leukaemia Biotinidase deficiency More trials…

    Learn about Rare Diseases

    Cholangitis sclerosing – Life with Disease Waldenstrom’s macroglobulinaemia – Life with Disease Pelizaeus-Merzbacher disease – Diagnostics Rhabdomyosarcoma – Trials in Disease Angiosarcoma metastatic – Basic Information Hereditary ataxia – Diagnostics Lennox-Gastaut syndrome – Diagnostics Sjogren’s syndrome Factor IX deficiency – Basic Information Crigler-Najjar syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vilobelimab Avapritinib Tianeptine Sodium Dexrazoxane Hydrochloride Corline Heparin Conjugate Dipyridamole Ofloxacin Hydrochloride Fedratinib Azd0901 L-Acetylleucine Purified Egg Phospholipids Ketoprofen Lysine Benztropine Mesylate Dog Epithelium Extract Tacrolimus Monohydrate Alirocumab Ide397 Zoledronic Acid Monohydrate Brepocitinib Tosilate Gen3017 More therapies…

    Learn about Your Condition

    Ophthalmoplegia Proteus syndrome Malignant neoplasm of choroid Anogenital dysplasia Arteriospasm coronary Cataract Pain Papillary thyroid cancer Pseudomonas infection Chronic myeloid leukaemia Osteonecrosis of jaw Laryngeal cancer Large cell lung cancer Meningococcal infection Petit mal epilepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myotonic dystrophy

  • A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    Belgium Denmark France Germany Italy The Netherlands +1

  • A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

    Recruiting

    2 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • ADS-019
    Belgium Germany Italy Spain

  • Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
    Denmark France Germany Italy The Netherlands Spain

  • Study on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I

    Recruiting

    1 1 1
    Investigated Drugs:
    • Vx-670
    Belgium France Germany Italy The Netherlands Spain

  • Study Comparing the Safety and Effectiveness of Mexiletine PR and Mexiletine IR for Adults with Non-Dystrophic Myotonias

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mexiletine
    • Mexiletine Hydrochloride
    Belgium France Germany Italy

  • Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

    Recruiting

    3 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Mexiletine Hydrochloride
    Belgium Denmark Germany Italy Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!